AI assistant
Sending…
PDS Biotechnology Corp — Director's Dealing 2016
Oct 27, 2016
34613_dirs_2016-10-27_8febac06-c1c6-4b48-8b58-86a140f4392f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-10-17
Reporting Person: BRENNAN DANIEL (Chief Operating Officer)
More from PDS Biotechnology Corp
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 1
Regulatory Filings
2026
Apr 27
Regulatory Filings
2026
Apr 15
Regulatory Filings
2026
Mar 30
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3